Breaking News

WuXi API Facility Passes FDA Inspection

August 18, 2014

To manufacture API for branded commercial drug

WuXiPharmaTech’s subsidiary, Shanghai SynTheAll Pharmaceutical Co. Ltd. (STA), passed an FDA inspection in July for the manufacture of the API for an undisclosed branded commercial drug.
 
This is the first FDA inspection of STA's facilities for the manufacture of an API. The company had previously received FDA approval for the manufacture of an advanced intermediate. STA provides process research to commercial manufacturing.
 
"We are very pleased to have passed a second FDA inspection of our manufacturing facilities," said Dr. Ge Li, chairman and chief executive officer of WuXiPharmaTech. "These favorable outcomes reflect our dedication to maintaining the highest quality standards throughout our organization."
blog comments powered by Disqus
  • API Sourcing Trends

    Kristin Brooks, Contract Pharma||April 11, 2016
    Drug product complexities, quality and regulatory hurdles drive market shift

  • U.S. Pharma Market Trends

    Kristin Brooks, Contract Pharma||April 8, 2016
    CPhI Report sees return of generic and API manufacturing to U.S. market

  • Flexible Manufacturing Strategies

    Kristin Brooks, Contract Pharma||April 4, 2016
    Michael Lehmann of Patheon discusses solutions for pharmaceutical forecasting errors

  • CMO Systems

    CMO Systems

    Philip K. Burns, CRO Consulting||April 5, 2016
    A CMO system includes four aspects of the product lifecycle: regulatory, technical, compliance, and operations.

  • Injectables: The New Oral?

    Injectables: The New Oral?

    Tugrul Kararli, Kurt Sedo, Josef Bossart, PharmaCircle LLC||April 5, 2016
    The growth trend of injectables continues across the pharma landscape.

  • Biopharmaceutical Contract Manufacturing Contract Negotiations

    Biopharmaceutical Contract Manufacturing Contract Negotiations

    William Downey, HighTech Business Decisions||April 5, 2016
    Navigating the complexities of supply agreements.